About inHEART, SAS
inHEART is a medical device company delivering the world's most advanced, AI-enabled digital twin of the heart to transform the treatment of cardiac arrhythmias. The company's proprietary segmentation algorithms analyze CT and MRI images to create sophisticated, cloud-based 3D cardiac models with unprecedented anatomical detail of tissue and structural characteristics. These digital twins provide cardiac electrophysiologists with detailed pre-procedural insights into each patient's unique cardiac anatomy, including cardiac structures, collateral anatomy, and myocardial tissue characteristics such as scar tissue, fatty infiltrate, and wall thinning. The platform seamlessly integrates with all major electroanatomic mapping (EAM) systems including Carto, Rhythmia, Ensite, and Affera for use during procedures. inHEART's solution has demonstrated significant clinical impact, with studies showing a 60% reduction in procedure times and 38% reduction in ventricular tachycardia recurrence rates compared to conventional approaches. The company serves over 300 partner hospitals across 40+ countries and has supported more than 7,500 cases. With headquarters in France and a US office in Cambridge, Massachusetts, inHEART is committed to providing all patients access to world-class cardiac imaging expertise to optimize treatment strategies, improve clinical outcomes, and return patients to full, healthy lives.
Mission & Story
Mission
We are committed to delivering the world's most sophisticated, AI-enabled, digital twin of the heart to advance the care of patients living with cardiac disease. We believe all patients deserve access to world-class expertise that guides and optimizes treatment strategies to support improved clinical outcomes and return patients to full, healthy lives.
Founding Story
The company originated from the MUSIC (Multi-modality Platform for Specific Imaging in Cardiology) research project at INRIA, a French research institute. CTO Loïc Cadour worked on this project at INRIA before it evolved into inHEART, which he joined in 2017.
Clinical Focus
Medical conditions and clinical areas addressed by inHEART, SAS.
Who It Serves
Milestones & Awards
Recent Milestones
Closed 750k€ funding round with SWEN Capital Partners in October 2024. Appointed Randy Jordan as Chairman of the Board in July 2025. Surpassed 7,500 cases supported across 300+ partner hospitals in 40+ countries.
Awards & Recognition
Featured on HRS (Heart Rhythm Society) TV
Key Partnerships
Social & Media
Latest Updates
inHEART welcomes Randy Jordan as new Chairman of the Board
1y ago
Don't miss these stories:
1y ago
inHEART closes 750k€ funding with SWEN Capital Partners
1y ago
Circle Cardiovascular Imaging Partners with inHEART to Distribute AI-Driven Digital Twin of the Heart for Advanced Cardiac Procedural Planning in the Electrophysiology Lab
2y ago
inHEART Raises $11M To Accelerate Development & Deployment of Novel Therapeutic, Predictive, and Screening Cardiac Solutions
2y ago
Company Details
- Founded
- 2017
- Headquarters
- Pessac, Nouvelle-Aquitaine, France
- Employees
- 1-10
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Anumana AI
series c · 175 employees
Anumana AI develops and delivers AI-driven ECG algorithms to enable early diagnosis and intervention for cardiovascular conditions.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.